Ticagrelor approved for acute coronary syndrome
- Review: Antiplatelet Therapy in Acute Coronary Syndromes. Aragam, Krishna G.; Bhatt, Deepak L. // Journal of Cardiovascular Pharmacology & Therapeutics;Mar2011, Vol. 16 Issue 1, p24
Antiplatelet therapy is integral to the acute and long-term management of acute coronary syndromes (ACSs) and for minimizing the thrombotic complications of percutaneous coronary intervention (PCI). This article reviews the most commonly used antiplatelet agents in ACS therapyâ€”aspirin,...
- The evolution of dual antiplatelet therapy in the setting of acute coronary syndrome: ticagrelor versus clopidogrel. Amico, Frank; Amico, Angela; Mazzoni, Jennifer; Moshiyakhov, Mark; Tamparo, William // Postgraduate Medicine;Mar2016, Vol. 128 Issue 2, p159
Review of: Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Eng J Med 2009; 361(11): 1045â€“1057. For acute coronary syndrome (ACS), a dual antiplatelet regimen comprised of treatment with aspirin and either P2Y12 adenosine...
- A case of paraplegia post treatment for acute coronary syndrome. Quraishi, S; Arya, S // British Journal of Hospital Medicine (17508460);Apr2013, Vol. 74 Issue 4, p231
Clinical images of an electrocardiogram (ECG) showing normal sinus rhythm which led t a provisional diagnosis of acute coronary syndrome and magnetic resonance image (MRI) of spine showing spinal haemorrhage, in a 59-year-old woman who presented with central chest tightness, are presented.
- Acute coronary syndrome: potent oral antiplatelets. Wright, Paul; Antoniou, Sotiris // Nurse Prescribing;Aug2013, Vol. 11 Issue 8, p397
The thienopyridine clopidogrel, which irreversibly blocks the adenosine diphosphate (ADP) receptor P2Y12 on platelets, has become an essential component of therapy in patients with acute coronary syndromes. However, clopidogrel has drawbacks which has led to the development of newer more potent...
- Managing Acute Coronary Syndrome: New Developments in Antiplatelet Therapy. Miller, Michael // Journal of Managed Care Medicine;2013, Vol. 16 Issue 3, p41
No abstract available.
- The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. Siller-Matula, Jolanta M.; Gruber, Carina; Francesconi, Marcel; Dechant, Cornelia; Jilma, Bernd; Delle-Karth, Georg; Grohs, Katharina; Podczeck-Schweighofer, Andrea; Christ, Günter // Clinical Science;Jan2015, Vol. 128 Issue 2, p121
This was a prospective study comparing two groups: personalized and non-personalized treatment with P2Y12 receptor blockers during a 12-month follow-up. We aimed to investigate whether personalized antiplatelet treatment in patients with high on-treatment platelet reactivity (HTPR) improves...
- Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Winter, Max-Paul; Koziński, Marek; Kubica, Jacek; Aradi, Daniel; Siller-Matula, Jolanta M. // Advances in Interventional Cardiology;2015, Vol. 11 Issue 4, p259
Antiplatelet therapy with P2Y12 receptor inhibitors has become the cornerstone of medical treatment in patients with acute coronary syndrome, after percutaneous coronary intervention and in secondary prevention of atherothrombotic events. Clopidogrel used to be the most broadly prescribed P2Y12...
- Bleeding, dyspnoea and discontinuation in a real world ACS cohort treated with ticagrelor. Harding, S.; Fairley, S.; Al-Sinan, A.; Holley, A.; Howard, C.; Matsis, P.; Aitken, A.; Larsen, P. // Heart, Lung & Circulation;2015 Supplement 3, Vol. 24, pS376
No abstract available.
- A Review of Antithrombotic Therapy and the Rationale and Design of the Randomized Edoxaban in Patients With Peripheral Artery Disease (ePAD) Trial Adding Edoxaban or Clopidogrel to Aspirin After Femoropopliteal Endovascular Intervention. Tangelder, Marco J. D.; Nwachuku, Chuke E.; Jaff, Michael; Baumgartner, Iris; Duggal, Anil; Adams, George; Ansel, Gary; Grosso, Michael; Mercuri, Michele; Shi, Minggao; Minar, Erich; Moll, Frans L. // Journal of Endovascular Therapy (Sage Publications Inc.);Apr2015, Vol. 22 Issue 2, p261
Compared with the coronary setting, knowledge about antithrombotic therapies after endovascular treatment (EVT) is inadequate in patients with peripheral artery disease (PAD). Based on a review of trials and guidelines, which is summarized in this article, there is scant evidence that...